

ISSN 2518-1491 (Online),
ISSN 2224-5286 (Print)

ҚАЗАҚСТАН РЕСПУБЛИКАСЫ
ҰЛТТЫҚ ҒЫЛЫМ АКАДЕМИЯСЫНЫҢ

Д.В.Сокольский атындағы «Жанармай,
катализ және электрохимия институты» АҚ

Х А Б А Р Л А Р Ы

ИЗВЕСТИЯ

НАЦИОНАЛЬНОЙ АКАДЕМИИ НАУК
РЕСПУБЛИКИ КАЗАХСТАН
АО «Институт топлива, катализа и
электрохимии им. Д.В. Сокольского»

NEWS

OF THE ACADEMY OF SCIENCES
OF THE REPUBLIC OF KAZAKHSTAN
JSC «D.V. Sokolsky institute of fuel, catalysis
and electrochemistry»

SERIES
CHEMISTRY AND TECHNOLOGY

6 (438)

NOVEMBER – DECEMBER 2019

PUBLISHED SINCE JANUARY 1947

PUBLISHED 6 TIMES A YEAR

ALMATY, NAS RK

NAS RK is pleased to announce that News of NAS RK. Series of chemistry and technologies scientific journal has been accepted for indexing in the Emerging Sources Citation Index, a new edition of Web of Science. Content in this index is under consideration by Clarivate Analytics to be accepted in the Science Citation Index Expanded, the Social Sciences Citation Index, and the Arts & Humanities Citation Index. The quality and depth of content Web of Science offers to researchers, authors, publishers, and institutions sets it apart from other research databases. The inclusion of News of NAS RK. Series of chemistry and technologies in the Emerging Sources Citation Index demonstrates our dedication to providing the most relevant and influential content of chemical sciences to our community.

Қазақстан Республикасы Ұлттық ғылым академиясы "ҚР ҰҒА Хабарлары. Химия және технология сериясы" ғылыми журналының Web of Science-тің жаңаланған нұсқасы Emerging Sources Citation Index-те индекстелуге қабылданғанын хабарлайды. Бұл индекстелу барысында Clarivate Analytics компаниясы журналды одан әрі the Science Citation Index Expanded, the Social Sciences Citation Index және the Arts & Humanities Citation Index-ке қабылдау мәселесін қарастыруда. Web of Science зерттеушілер, авторлар, баспашылар мен мекемелерге контент тереңдігі мен сапасын ұсынады. ҚР ҰҒА Хабарлары. Химия және технология сериясы Emerging Sources Citation Index-ке енуі біздің қоғамдастық үшін ең өзекті және беделді химиялық ғылымдар бойынша контентке адалдығымызды білдіреді.

НАН РК сообщает, что научный журнал «Известия НАН РК. Серия химии и технологий» был принят для индексирования в Emerging Sources Citation Index, обновленной версии Web of Science. Содержание в этом индексировании находится в стадии рассмотрения компанией Clarivate Analytics для дальнейшего принятия журнала в the Science Citation Index Expanded, the Social Sciences Citation Index и the Arts & Humanities Citation Index. Web of Science предлагает качество и глубину контента для исследователей, авторов, издателей и учреждений. Включение Известия НАН РК в Emerging Sources Citation Index демонстрирует нашу приверженность к наиболее актуальному и влиятельному контенту по химическим наукам для нашего сообщества.

Б а с р е д а к т о р ы
х.ғ.д., проф., ҚР ҰҒА академигі **М.Ж. Жұрынов**

Р е д а к ц и я а л қ а с ы:

Ағабеков В.Е. проф., академик (Белорус)
Волков С.В. проф., академик (Украина)
Воротынцев М.А. проф., академик (Ресей)
Газалиев А.М. проф., академик (Қазақстан)
Ергожин Е.Е. проф., академик (Қазақстан)
Жармағамбетова А.К. проф. (Қазақстан), бас ред. орынбасары
Жоробекова Ш.Ж. проф., академик (Қырғыстан)
Иткулова Ш.С. проф. (Қазақстан)
Манташян А.А. проф., академик (Армения)
Пралиев К.Д. проф., академик (Қазақстан)
Баешов А.Б. проф., академик (Қазақстан)
Бүркітбаев М.М. проф., академик (Қазақстан)
Джусипбеков У.Ж. проф. корр.-мүшесі (Қазақстан)
Молдахметов М.З. проф., академик (Қазақстан)
Мансуров З.А. проф. (Қазақстан)
Наурызбаев М.К. проф. (Қазақстан)
Рудик В. проф., академик (Молдова)
Рахимов К.Д. проф. академик (Қазақстан)
Стрельцов Е. проф. (Белорус)
Тәшімов Л.Т. проф., академик (Қазақстан)
Тодераш И. проф., академик (Молдова)
Халиков Д.Х. проф., академик (Тәжікстан)
Фарзалиев В. проф., академик (Әзірбайжан)

«ҚР ҰҒА Хабарлары. Химия және технология сериясы».

ISSN 2518-1491 (Online),

ISSN 2224-5286 (Print)

Меншіктенуші: «Қазақстан Республикасының Ұлттық ғылым академиясы» Республикалық қоғамдық бірлестігі (Алматы қ.)

Қазақстан республикасының Мәдениет пен ақпарат министрлігінің Ақпарат және мұрағат комитетінде 30.04.2010 ж. берілген №1089-Ж мерзімдік басылым тіркеуіне қойылу туралы куәлік

Мерзімділігі: жылына 6 рет.

Тиражы: 300 дана.

Редакцияның мекенжайы: 050010, Алматы қ., Шевченко көш., 28, 219 бөл., 220, тел.: 272-13-19, 272-13-18,
<http://chemistry-technology.kz/index.php/en/arihiv>

© Қазақстан Республикасының Ұлттық ғылым академиясы, 2019

Типографияның мекенжайы: «Аруна» ЖК, Алматы қ., Муратбаева көш., 75.

Главный редактор
д.х.н., проф., академик НАН РК **М. Ж. Журинов**

Редакционная коллегия:

Агабеков В.Е. проф., академик (Беларусь)
Волков С.В. проф., академик (Украина)
Воротынцев М.А. проф., академик (Россия)
Газалиев А.М. проф., академик (Казахстан)
Ергожин Е.Е. проф., академик (Казахстан)
Жармагамбетова А.К. проф. (Казахстан), зам. гл. ред.
Жоробекова Ш.Ж. проф., академик (Кыргызстан)
Иткулова Ш.С. проф. (Казахстан)
Манташян А.А. проф., академик (Армения)
Пралиев К.Д. проф., академик (Казахстан)
Баешов А.Б. проф., академик (Казахстан)
Буркитбаев М.М. проф., академик (Казахстан)
Джусипбеков У.Ж. проф. чл.-корр. (Казахстан)
Мулдахметов М.З. проф., академик (Казахстан)
Мансуров З.А. проф. (Казахстан)
Наурызбаев М.К. проф. (Казахстан)
Рудик В. проф., академик (Молдова)
Рахимов К.Д. проф. академик (Казахстан)
Стрельцов Е. проф. (Беларусь)
Ташимов Л.Т. проф., академик (Казахстан)
Тодераш И. проф., академик (Молдова)
Халиков Д.Х. проф., академик (Таджикистан)
Фарзалиев В. проф., академик (Азербайджан)

«Известия НАН РК. Серия химии и технологии».

ISSN 2518-1491 (Online),

ISSN 2224-5286 (Print)

Собственник: Республиканское общественное объединение «Национальная академия наук Республики Казахстан» (г. Алматы)

Свидетельство о постановке на учет периодического печатного издания в Комитете информации и архивов Министерства культуры и информации Республики Казахстан №10893-Ж, выданное 30.04.2010 г.

Периодичность: 6 раз в год

Тираж: 300 экземпляров

Адрес редакции: 050010, г. Алматы, ул. Шевченко, 28, ком. 219, 220, тел. 272-13-19, 272-13-18,
<http://chemistry-technology.kz/index.php/en/arhiv>

© Национальная академия наук Республики Казахстан, 2019

Адрес редакции: 050100, г. Алматы, ул. Кунаева, 142,
Институт органического катализа и электрохимии им. Д. В. Сокольского,
каб. 310, тел. 291-62-80, факс 291-57-22, e-mail:orgcat@nursat.kz

Адрес типографии: ИП «Аруна», г. Алматы, ул. Муратбаева, 75

NEWS

OF THE NATIONAL ACADEMY OF SCIENCES OF THE REPUBLIC OF KAZAKHSTAN

SERIES CHEMISTRY AND TECHNOLOGY

ISSN 2224-5286

<https://doi.org/10.32014/2019.2518-1491.71>

Volume 6, Number 438 (2019), 36 – 41

UDC 541.64

**Ye.M. Tazhbayev¹, A.A. Bakibaev², A.T. Takibayeva³, T.S. Zhumagalieva¹,
L.Zh. Zhaparova¹, A.A. Agdarbek¹, N.Zh. Gazizova¹, O.E. Mukashev¹, A.M. Tazhibay³**

¹Academician E.A.Buketov Karaganda State University, Karaganda, Kazakhstan;

²Tomsk State University, Tomsk, Russia;

³Karaganda State Technical University, Karaganda, Kazakhstan

E-mail: zhumagalieva79@mail.ru, ayaulym_agdarbek@mail.ru

PREPARATION OF POLYMERIC NANOPARTICLES OF ALBUMIN AND IMMOBILIZATION OF THEM WITH THE ANTICANCER DRUG “CYCLOPHOSPHANE”

Abstract. Nanoparticles based on biodegradable and biocompatible polymers allow to attain the targeted drug delivery to the specific organ, without affecting healthy cells of the body and prolonging the therapeutic effect of the drug substance. This study is devoted to the development of the method for the preparation of nanoparticles of human serum albumin (HSA) immobilized with the anticancer drug Cyclophosphamide. Albumin nanoparticles with the sizes of 150-170 nm and narrow particle size distribution (PDI 0.069-0.116) were obtained by coacervation. The yield of nanoparticles is 88.5%. The degree of binding of the drug to polymer nanoparticles was within the range of 54.6% to 92.4%. The drug release was prolonged. After 42 hours 68-77% of the biologically active substance was released from the polymer matrix. It is concluded that the development of HSA-based nanocarrier is promising for the Cyclophosphamide preparation.

Keywords: nanoparticles, drug carriers, human serum albumin, cyclophosphane, cyclophosphamide, anticancer drug.

Introduction

One of the serious diseases leading to death worldwide is cancer. Traditionally, cancer is treated using methods of radiation therapy, chemotherapy and surgery [1]. In order to solve the problems associated with reducing the dosage of the drug and minimize side effects, it is important to use the method of targeted drug delivery using the polymeric nanoparticles and nanocapsules. Nanotechnology-based cancer therapy became one of the promising areas of biomedicine that has been widely studied over the past few decades.[2] The use of nanoparticles in the treatment of cancer overcomes the disadvantages of conventional drug delivery systems, such as nonspecific biodistribution and targeting, insufficient solubility in water, poor oral bioavailability and low therapeutic parameters [3, 4, 5].

Among the main requirements for polymer carriers, the stability and inertness to the blood components should be outlined; also the polymer should protect the drug substance from degradation [6,7]. Human serum albumin was chosen as the polymeric carrier in this work. Albumin is a favorable macromolecular carrier and is widely used in medicine owing to its biodegradability, non-toxicity and non-immunogenicity [8,9]. The incorporation of a drug into albumin nanoparticles is an attempt to carry out the targeted delivery of drug to tumor cells to reduce side effects of the drug. Presently the antitumor drug preparations based on albumin nanoparticles have already been created, but their price is so high that it makes them inaccessible. One of the reasons for the inaccessibility of anticancer drugs created on the basis of nanoparticles is complex synthesis techniques, high energy consumption and instability of nanosystems [10]. To overcome these difficulties, in the framework of this study an attempt was made to develop a relatively simple method for producing albumin nanoparticles, to achieve a high degree of drug immobilization, and to obtain a drug with the potential for prolonged release.

Cyclophosphamide was chosen as a model preparation for immobilization. Cyclophosphamide is a cytostatic antitumor chemotherapeutic drug of an alkylating type of action; a derivative of bis-chloroethylamine and simultaneously a derivative of oxazaphosphorine or a derivative of diamidophosphate (the so-called "phosphoramidate mustard"). It is recommended for the treatment of many forms of cancer, including small cell lung cancer, cancer of the ovary, cervix and body of the uterus, breast cancer and others. The drug has many side effects and limitations due to its toxicity and effects on healthy body cells, etc. Thus, ensuring the safety and effectiveness of treatment with this drug is relevant and can be solved using polymeric drug carriers.

Methods

Synthesis of polymer nanoparticles by the incorporation method

Albumin-based nanoparticles of Cyclophosphamide were synthesized using the incorporation method. To an aqueous solution of albumin (2%) was added with a certain speed (not more than 1 ml/min) a solution of the drug in ethanol with concentrations of 2; 4; 8 mg/ml (pH of the solution is 8.0-8.5). The particles formed in this process are small in size (within the range of 50-300 nm). To crosslink the particles glutaraldehyde (6.25% solution) was added to the solution, which stabilized the size and the structure of the particles. Incubation was carried out for 2 hours on a mechanical stirrer (650 rpm). The solution of unreacted serum albumin was purified by washing it three times with deionized water and centrifuging for 15 minutes at 14500 rpm. The obtained nanoparticles were separated by centrifugation (MiniSpin Plus 14500, Eppendorf, Hamburg, Germany). The yield of nanoparticles was determined by gravimetry.

Determination of particle size and polydispersity

The average size of nanoparticles and their polydispersity were determined using photon correlation spectroscopy (FCC) at a Malvern Zetasizer Nano S90 instrument (Malvern Instruments Ltd., UK) at a temperature of 298 K and a scattering angle of 90°. Each nanoparticle sample was properly diluted with a non-solvent immediately after preparation. The average size and polydispersity index were measured three times for each batch.

Analysis of Nanoparticles Morphology

Nanoparticles' morphology was analyzed by scanning electron microscopy (SEM) using a MIRA 3 LM TESCAN electron microscope (Czech Republic). Carbon was sprayed onto the surface of the samples using magnetron sputtering of carbon fiber to increase conductivity. The measurements were carried out in high vacuum using an SE detector at an accelerating voltage of 4–20 kV.

Investigation of the binding degree of cyclophosphamide with the polymeric nanoparticles

To determine the binding degree of drug to albumin NPs, the obtained particles were separated from the supernatant by ultracentrifugation at 14500 rpm and washed with water. The content of unbound drug was determined spectrophotometrically using a UV-1800 SHIMADZU instrument (Japan) ($\lambda = 247.5$ nm).

The Study of Cyclophosphamide Release

The kinetics of drug release from serum albumin NPs was studied using standard methods in phosphate buffered saline at a temperature of 310 K (pH = 7.4). For this, a weighed portion of nanoparticles loaded with cyclophosphamide was dispersed in 10 ml of a phosphate buffer solution. Within 2 days, 2 ml samples were taken from the dispersion at certain time intervals, which were centrifuged at a speed of 14500 rpm. The concentration of the drug in the solution was determined using UV spectroscopy at 247.5 nm [12].

Results and discussion

According to the method described above, an alcoholic drug solution was added to the albumin solution.

The concentration of the drug ranged from 2 to 8 mg/ml. To stabilize the nanoparticles they were crosslinked with glutaraldehyde. The physicochemical characteristics of the particles were determined by photon correlation spectroscopy (PCS). The results of measurements of particle size and polydispersity index are presented in Figure 1 and Table 1. As can be seen from the figure, the obtained nanoparticles have satisfactory physicochemical characteristics: the average particle size was at the range of 148 - 171.5, and the value of polydispersity index is in the interval of 0.0038-0.098. The formation of large particles is not observed in the system, and the particles are uniformly distributed.




Figure 1 - PCS data and electron microscopic photographs of serum albumin nanoparticles immobilized with cyclophosphamide at concentrations of a) 2 mg / ml; b) 4 mg / ml; c) 8 mg / ml

To confirm the data obtained by the PCS the electron microscopic images of polymeric nanoparticles loaded with cyclophosphamide were made using a scanning electron microscope (Figure 1 a, b, c).

From electron microscopic images (Figure 1), it can be seen that the polymeric nanoparticles have spherical shape and they are uniformly distributed in size and shape: the average particle size of nanoparticles of all concentrations varies from 100 - 300 nm. It was found that with increasing the concentration of the drug the size of the polymeric nanoparticles increases, but their meanings meet the requirements to the nanoparticles for invasive administration. These parameters indicate that the obtained nanoparticles can be used as transporting systems.

The binding degree is an important quantity that characterizes the quantification of the immobilization of a drug substance in a polymer matrix. Therefore, the next step in our study was to determine the binding degree of the cyclophosphamide with albumin nanoparticles. It was found that the binding degree

of cyclophosphamide in the samples reached 92.4% depending on the concentration of the drug (table 1). In this case, the increase in the concentration of the drug in the solution leads to the increase in its content in the polymeric nanoparticles.

Table 1 - Physicochemical characteristics of albumin nanoparticles immobilized with cyclophosphamide

C_{ds} , mg/ml	d, nm	PDI	The yield of the particles with the size up to 1000 nm, %	The binding degree, %	The degree of release, %	The yield of nanoparticles, %
2	140.9	0.154	100	54.6	68.2	70.5
	148.9	0.085	100			
	143.8	0.116	100			
4	152.4	0.038	98.5	79.4	71.5	75.3
	149.1	0.085	100			
	151.2	0.086	99.5			
8	172.6	0.134	100	92.4	77.1	88.5
	171.5	0.098	100			
	168.8	0.116	100			

At the next stage, the release of cyclophosphamide from albumin nanoparticles was studied. The release kinetics was studied under conditions close to physiological (in phosphate-buffered saline at a temperature of 310 K, pH = 7.4) for 2 days. The results of this study are presented in Figure 2.




Figure 2 - Kinetics of cyclophosphamide release from NPs

All release curves of cyclophosphamide from the albumin matrix are characterized by the presence of several sites. The first four hours are characterized by the highest speed, when 24-34% of the drug is released which probably characterizes the release of an unbound drug from the surface layer of albumin. This indicates the retention of the drug in the albumin nanoparticles via non-chemical bonds, possibly via hydrogen, van der Waals, and other bonds. Only after 42 hours the concentration of the drug reaches saturation in solution and its amount is 68-77% depending on the initial concentration. These results point on promising further studies in the field of the creation of prolonged forms of the drug.

Conclusion

It was possible to develop a method for the synthesis of nanometric polymer carriers based on a biocompatible and biodegradable albumin polymer for transporting the anticancer drug Cyclophosphamide. Nanoparticles with satisfactory physicochemical characteristics have been synthesized using incorporation method. It makes them promising systems for targeted drug delivery. The use of such new dosage forms in the form of nanoparticles will reduce the daily dose of the drug, increase its effectiveness and minimize its side effects.

**Е.М. Тажбаев¹, А.А. Бакибаев², А.Т. Такибаева³, Т.С. Жумагалиева¹,
Л.Ж. Жапарова¹, А.А. Ағдарбек¹, Н.Ж. Газизова¹, О.Е. Мукашев¹, А.М. Тәжібай³**

¹Е.А.Бөкетов атындағы Қарағанды Мемлекеттік Университеті, Қарағанды, Қазақстан

²Томский Государственный Университет, Томск, Россия

³Қарағанды Мемлекеттік Техникалық Университеті, Қарағанды, Қазақстан

АЛЬБУМИННИҢ ПОЛИМЕРЛІ НАНОБӨЛШЕКТЕРІН АЛУ ЖІНЕ ОЛАРДЫ ҚАТЕРЛІ ІСІККЕ ҚАРСЫ ПРЕПАРАТ «ЦИКЛОФОСФАНМЕН» ИММОБИЛИЗАЦИЯЛАУ

Аннотация. Биодырамалы және биоүйлесімді полимерлердің негізіндегі нанобөлшектер дәрілік заттың терапевтикалық әсер ету уақытын ұзарта отырып, сонымен қатар ағзаның сау жасушаларын зақымдамай дәрілік затты мақсатты түрде тікелей нысана ағзаға жеткізуге мүмкіндік береді. Бұл зерттеу қатерлі ісікке қарсы «Циклофосфан» препаратымен иммобилизацияланған адам сарысулы альбуминінің нанобөлшектерін алу жолдарын жасап шығаруға арналған. Коацервация әдісімен 150-170 нм өлшемдегі, полидисперстілік мәні төмен (полидисперстілік индексі 0,069-0,116) альбумин нанобөлшектері алынды. Нанобөлшектердің шығымы 88,5%-ды құрады. Дәрілік заттың полимерлі нанобөлшектермен байланысу дәрежесі 54,6% және 92,4% аралығында болды. Дәрілік заттың босап шығуы пролонгациялық түрде жүрді. 42 сағаттан кейін полимерлі матрицадан биологиялық белсенді заттың 68-77%-ы ортаға босап шықты. «Циклофосфан» препаратына адам сарысулы альбумині негізіндегі нанотасымалдаушыны жасап шығарудың болашағы зор деген қорытынды жасалынды.

Түйін сөздер: нанобөлшектер, дәрі тасымалдаушылар, адам сарысулы альбумині, циклофосфан, циклофосфамид, қатерлі ісікке қарсы препарат.

**Е.М. Тажбаев¹, А.А. Бакибаев², А.Т. Такибаева³, Т.С. Жумагалиева¹,
Л.Ж. Жапарова¹, А.А. Ағдарбек¹, Н.Ж. Газизова¹, О.Е. Мукашев¹, А.М. Тәжібай³**

¹Қарагандинский Государственный Университет им. Е.А.Букетова, Караганда, Казахстан

²Томский Государственный Университет, Томск, Россия

³Қарагандинский Государственный Технический Университет, Караганда, Казахстан

ПОЛУЧЕНИЕ ПОЛИМЕРНЫХ НАНОЧАСТИЦ АЛЬБУМИНА И ИХ ИММОБИЛИЗАЦИЯ ПРОТИВООПУХОЛЕВЫМ ПРЕПАРАТОМ «ЦИКЛОФОСФАН»

Аннотация. Наночастицы на основе биодegradуемых и биосовместимых полимеров дают возможность целенаправленно доставлять лекарственное вещество непосредственно в орган-мишень, при этом не поражая здоровые клетки организма и продлевая срок терапевтического действия лекарственного вещества. Настоящее исследование посвящено разработке способа получения наночастиц человеческого сывороточного альбумина (ЧСА), иммобилизованного противоопухолевым препаратом «Циклофосфан». Методом коацервации получены наночастицы альбумина с размерами 150-170 нм, узкой полидисперсностью (индекс полидисперсности 0,069-0,116). Выход наночастиц составил до 88,5%. Степень связывания лекарства с полимерными наночастицами находилась в пределах 54,6% до 92,4%. Высвобождение препарата происходило пролонгированно. Через 42 часа из полимерной матрицы высвободилось 68-77% биологически-активного вещества. Сделан вывод о перспективности создания наноносителя на основе ЧСА для препарата «Циклофосфан».

Ключевые слова: наночастицы, носители лекарств, человеческий сывороточный альбумин, циклофосфан, циклофосфамид, противоопухолевый препарат.

Information about authors:

Yerkeblan M. Tazhbayev - Academician E.A. Buketov Karaganda State University, Vice Rector for Innovation in Science and Technology, Dr. Chem. Sci., professor, E-mail address: tazhbaev@mail.ru, <https://orcid.org/0000-0003-2043-6672>

Abdigali A. Bakibaev - Tomsk State University, Leading Researcher, Dr. Chem. Sci., professor, E-mail address: bakibaev@mail.ru, <https://orcid.org/0000-0002-3335-3166>

Altynarai T. Takibayeva – Karaganda State Technical University, Cand. Chem. Sci., E-mail address: altynarai81@mail.ru, <https://orcid.org/0000-0003-0536-0817>

Tolkyn S. Zhumagalieva – Academician E.A. Buketov Karaganda State University, Cand. Chem. Sci., E-mail address: zhumagalieva79@mail.ru, <https://orcid.org/0000-0003-1765-752X>

Lyazzat Zh. Zhaparova – Academician E.A. Buketov Karaganda State University, PhD, E-mail address: lyazzh@mail.ru, <https://orcid.org/0000-0003-1894-0255>

Ayaulym A. Agdarbek – Academician E.A. Buketov Karaganda State University, 2nd year Master student, E-mail address: ayaulym_agdarbek@mail.ru, <https://orcid.org/0000-0001-8808-8315>

Nazgul Zh. Gazizova – Academician E.A. Buketov Karaganda State University, 2nd year Master student, E-mail address: gazizovanz@gmail.com, <https://orcid.org/0000-0002-9692-2768>

Olzhas E. Mukashev - Academician E.A. Buketov Karaganda State University, 3rd year–PhD Student, E-mail address: mukashevoe@gmail.com, <https://orcid.org/0000-0002-8040-6515>

Aizhan M. Tazhibay - Karaganda State Technical University, 2nd year Master student, E-mail address: aika_93_16@mail.ru, <https://orcid.org/0000-0001-8190-3647>

REFERENCES

- [1] Urruticoechea A., Alemany R., Balart J., Villanueva A., Vicals F., Capelló G. Recent advances in cancer therapy: An overview. *Curr. Pharm. Des.* 2010;16:3–10.
- [2] *Nanotechnology in Medicine and the Biosciences*, by Coombs RRH, Robinson DW. 1996, ISBN 2-88449-080-9.
- [3] Cai W, Gao T, Hong H, Sun J (2008) Applications of gold nanoparticles in cancer nanotechnology. *Nanotechnol Sci Appl* 1(1):17–32
- [4] Sultana N, Shenoy SB, Sham ME, Keshav S, Kaul R (2012) Nanogoldtechnology-imaging, sensing and target therapy in head and neck cancer. *Clin Cancer Investig J* 1(1):6–12
- [5] Nie, Shuming, Yun Xing, Gloria J. Kim, and Jonathan W. Simmons (2007). «Nanotechnology Applications in Cancer». *Annual Review of Biomedical Engineering* 9: 257–88. DOI:10.1146/annurev.bioeng.9.060906.152025. PMID 17439359.
- [6] I. Vural, H.S. Kas, A.A. Hincal, G. Cavcè, J. Microencapsulation 4 (7) (1990) 511–516.
- [7] Mudshinge SR, Deore AB, Patil S, Bhalgat CM. Nanoparticles: emerging carriers for drug delivery. *Saudi Pharm J SPJ Off Publ Saudi Pharm Soc.* 2011;19(3) :129–41. doi:10.1016/j.jsps.2011.04.001.
- [8] Lordick F., Hacker U. In: *Chemotherapy and Targeted Therapy, in Imaging of Complications and Toxicity following Tumor Therapy*. Kauczor H.-U., Buerle T., editors. Springer International Publishing; Cham (ZG, Switzerland): 2015. pp. 3–15.
- [9] G.V. Patil, Biopolymer albumin for diagnosis and in drug delivery, *Drug Dev. Res.* 58 (2003) 219–247.
- [10] Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles // *J. Cont. Rel.* 2008. 132. P. 171-183.
- [11] Bayeshov A., Abijanova D. A., Abduvalieva U. A., Zhurinov M. (2019) Study of electrochemical properties of copper in solution of sulphuric acid with copper (II) ions and titan through potentiodynamic polarized curve // *Bulletin of national academy of sciences of the Republic of Kazakhstan.* 2019. Vol. 2, N378. P.241-248. ISSN 1991-3494 (Print). <https://doi.org/10.32014/2019.2518-1467.62>
- [12] E.M. Tazhbaev, M.Zh. Burkeev, L.Zh. Zhaparova, T.S. Zhumagalieva, A.A. Agdarbek (2019) Albumin nanoparticles loaded with the antitumor drug “Hydroxycarbamide” by the incorporation method // *Bulletin of the Karaganda University, Chemistry series.* 2019. Vol.1 (93), P. 48-53. ISSN 2518-718X. DOI: 10.31489/2019Ch1/54-59

Publication Ethics and Publication Malpractice in the journals of the National Academy of Sciences of the Republic of Kazakhstan

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

Submission of an article to the National Academy of Sciences of the Republic of Kazakhstan implies that the described work has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. In particular, translations into English of papers already published in another language are not accepted.

No other forms of scientific misconduct are allowed, such as plagiarism, falsification, fraudulent data, incorrect interpretation of other works, incorrect citations, etc. The National Academy of Sciences of the Republic of Kazakhstan follows the Code of Conduct of the Committee on Publication Ethics (COPE), and follows the COPE Flowcharts for Resolving Cases of Suspected Misconduct (http://publicationethics.org/files/u2/New_Code.pdf). To verify originality, your article may be checked by the Cross Check originality detection service <http://www.elsevier.com/editors/plagdetect>.

The authors are obliged to participate in peer review process and be ready to provide corrections, clarifications, retractions and apologies when needed. All authors of a paper should have significantly contributed to the research.

The reviewers should provide objective judgments and should point out relevant published works which are not yet cited. Reviewed articles should be treated confidentially. The reviewers will be chosen in such a way that there is no conflict of interests with respect to the research, the authors and/or the research funders.

The editors have complete responsibility and authority to reject or accept a paper, and they will only accept a paper when reasonably certain. They will preserve anonymity of reviewers and promote publication of corrections, clarifications, retractions and apologies when needed. The acceptance of a paper automatically implies the copyright transfer to the National Academy of Sciences of the Republic of Kazakhstan.

The Editorial Board of the National Academy of Sciences of the Republic of Kazakhstan will monitor and safeguard publishing ethics.

Правила оформления статьи для публикации
в журнале смотреть на сайте:

www.nauka-nanrk.kz

<http://chemistry-technology.kz/index.php/en/arhiv>

ISSN 2518-1491 (Online), ISSN 2224-5286 (Print)

Редакторы: *М. С. Ахметова, Т. А. Апендиев, Аленов Д.С.*
Верстка на компьютере *А.М. Кульгинбаевой*

Подписано в печать 05.12.2019.
Формат 60x881/8. Бумага офсетная. Печать – ризограф.
5,25 п.л. Тираж 300. Заказ 6.